Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06898957 |
| Title | Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) ((DeLLphi-310)) |
| Acronym | (DeLLphi-310) |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Amgen |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA | ITA | HUN | GRC | FRA | ESP | DEU | CAN |